These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20233349)

  • 1. Absence of detection of novel human parvoviruses in German plasma donations.
    Eis-Hübinger AM; Drexler JF; Reber U; Panning M; Drosten C; Weber-Schehl M; Hedges D; Baylis SA; Roth WK
    Transfusion; 2010 Jan; 50(1):266-7. PubMed ID: 20233349
    [No Abstract]   [Full Text] [Related]  

  • 2. Human parvovirus 4 in recipients of cellular products and in blood donors: epidemiologic similarity with B19 parvovirus.
    Servant-Delmas A; Laperche S; Mercier M; Elghouzzi MH; Lionnet F; Stankovic K; Girot R; Lefrère JJ
    Transfusion; 2009 Aug; 49(8):1771-3. PubMed ID: 19732407
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.
    Henriques I; Monteiro F; Meireles E; Cruz A; Tavares G; Ferreira M; Araújo F
    Transfus Apher Sci; 2005 Nov; 33(3):305-9. PubMed ID: 16203176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parvovirus B19. Position of the Blood Working Group of the Federal Ministry of Health].
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Sep; 53(9):944-56. PubMed ID: 20853092
    [No Abstract]   [Full Text] [Related]  

  • 5. Presence and significance of parvovirus B19 in blood and blood products.
    Siegl G; Cassinotti P
    Biologicals; 1998 Jun; 26(2):89-94. PubMed ID: 9811511
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel parvovirus and related variant in human plasma.
    Fryer JF; Kapoor A; Minor PD; Delwart E; Baylis SA
    Emerg Infect Dis; 2006 Jan; 12(1):151-4. PubMed ID: 16494735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals.
    Fryer JF; Delwart E; Hecht FM; Bernardin F; Jones MS; Shah N; Baylis SA
    Transfusion; 2007 Jun; 47(6):1054-61. PubMed ID: 17524097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay.
    Kleinman SH; Glynn SA; Lee TH; Tobler L; Montalvo L; Todd D; Kiss JE; Shyamala V; Busch MP;
    Transfusion; 2007 Oct; 47(10):1756-64. PubMed ID: 17880600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area.
    Parsyan A; Addo-Yobo E; Owusu-Ofori S; Akpene H; Sarkodie F; Allain JP
    Transfusion; 2006 Sep; 46(9):1593-600. PubMed ID: 16965589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
    Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
    Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of red cell substitutes on the blood service in Japan.
    Sekiguchi S
    Artif Cells Blood Substit Immobil Biotechnol; 1997; 25(1-2):53-60. PubMed ID: 9083626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parvovirus PARV4 visualization and detection.
    Tuke PW; Parry RP; Appleton H
    J Gen Virol; 2010 Feb; 91(Pt 2):541-4. PubMed ID: 19846677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products.
    Plentz A; Hahn J; Knöll A; Holler E; Jilg W; Modrow S
    Transfusion; 2005 Nov; 45(11):1811-5. PubMed ID: 16271109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human parvovirus PARV4 in clotting factor VIII concentrates.
    Fryer JF; Hubbard AR; Baylis SA
    Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Viral safety in hemotherapy. Current aspects of hepatitis C and parvovirus B19 detection for plasma component therapy].
    Sibrowski W; Kühnl P
    Beitr Infusionsther; 1990; 26():22-6. PubMed ID: 1703836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of Parvovirus 4 and KI/WU polyomaviruses in HIV-positive blood donations, France.
    Touinssi M; Galicher V; de Micco P; Biagini P
    J Clin Virol; 2016 Jan; 74():43-4. PubMed ID: 26655267
    [No Abstract]   [Full Text] [Related]  

  • 17. [Parvovirus B19 infection in patients with congenital blood coagulation disorders].
    Aguilar Franco C; Lucía Cuesta JF; Ferrer Torres J; Omeñaca Teres M
    Med Clin (Barc); 1997 May; 108(17):641-6. PubMed ID: 9312580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of parvovirus B19 to inactivation by liquid heating in plasma products.
    Hattori S; Yunoki M; Tsujikawa M; Urayama T; Tachibana Y; Yamamoto I; Yamamoto S; Ikuta K
    Vox Sang; 2007 Feb; 92(2):121-4. PubMed ID: 17298573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIDS row closes German health office.
    Karcher HL
    BMJ; 1993 Oct; 307(6911):1023. PubMed ID: 8251775
    [No Abstract]   [Full Text] [Related]  

  • 20. Human parvovirus infections--a haematological perspective: any relevance to New Zealand health?
    Blacklock H
    N Z Med J; 1989 Aug; 102(874):436-7. PubMed ID: 2548133
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.